Document Detail

Cell therapy for type 2 diabetes: is it desirable and can we get it?
MedLine Citation:
PMID:  18834449     Owner:  NLM     Status:  MEDLINE    
The functional mass of beta-cells is decreased in type 2 diabetes. Replacing missing beta-cells or triggering their regeneration may thus allow for improved treatment of type 2 diabetes, to the extent that this is combined with therapy for improved insulin sensitivity. Although progress has been made in deriving beta-cell-like cells from stem or precursor cells in vitro, these cannot yet be obtained in sufficient quantities or well enough differentiated to envisage their therapeutic use in beta-cell replacement therapy. Likewise, our very limited understanding of beta-cell regeneration in adult man does not yet allow for development of a valid strategy for kick-starting such a process in individuals with type 2 diabetes, whether by bona fide neogenesis or self-replication of existing beta-cells. Regardless of how beta-cell mass is restored in type 2 diabetes, it will be important to prevent any renewed decrease thereafter. Current understanding suggests that islet inflammation as well as signals from (insulin-resistant/inflamed) adipose tissue and skeletal muscle contribute towards decreased beta-cell mass in type 2 diabetes. It will likely be important to protect newly formed or implanted beta-cells from these negative influences to ensure their long-term survival.
P A Halban
Related Documents :
24969979 - Short-reactivation of neurogenin-3 and mesenchymal microenvironment is require for β-c...
3159609 - Chlorozocin. a diabetogenic analogue of streptozocin with dissimilar mechanisms of acti...
8627419 - Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human...
3514609 - Inhibition of post-translational modification and surface expression of a melanoma-asso...
10194529 - Beta-cell gene expression and functional characterisation of the human insulinoma cell ...
8250289 - Temporal coincidence of the appearance of elongated spermatids and of histochemical rea...
10636889 - Up-regulation of multidrug resistance p-glycoprotein via nuclear factor-kappab activati...
422679 - Analysis of the significance of a periodic, cell size-controlled doubling in rates of m...
16510219 - Cardiac metastasis after squamous cell carcinoma of the oral cavity: case report.
Publication Detail:
Type:  Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  10 Suppl 4     ISSN:  1463-1326     ISO Abbreviation:  Diabetes Obes Metab     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-06     Completed Date:  2008-12-09     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  205-11     Citation Subset:  IM    
Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Diabetes Mellitus, Type 2 / physiopathology,  therapy*
History, 18th Century
History, 19th Century
History, 20th Century
History, 21st Century
Insulin Resistance / physiology*
Islets of Langerhans / cytology*,  physiology
Stem Cell Transplantation / methods*,  trends
Tissue Therapy / methods*,  trends

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Insulitis in type 2 diabetes.
Next Document:  Antenatal syphilis serology in pregnant women and follow-up of their infants in northern Italy.